-
1
-
-
35348845728
-
Emerging oral therapies for multiple sclerosis
-
Cohen BA, Rieckmann P. Emerging oral therapies for multiple sclerosis. Int J Clin Pract 2007; 61:1922-1930.
-
(2007)
Int J Clin Pract
, vol.61
, pp. 1922-1930
-
-
Cohen, B.A.1
Rieckmann, P.2
-
2
-
-
0034073705
-
Therapeutic developments in multiple sclerosis
-
Goodin DS. Therapeutic developments in multiple sclerosis. Expert Opin Invest Drugs 2000; 9:655-670.
-
(2000)
Expert Opin Invest Drugs
, vol.9
, pp. 655-670
-
-
Goodin, D.S.1
-
3
-
-
33744488268
-
Emerging therapeutic targets in multiple sclerosis
-
Fontoura P, Steinman L, Miller A. Emerging therapeutic targets in multiple sclerosis. Curr Opin Neurol 2006; 19:260-266.
-
(2006)
Curr Opin Neurol
, vol.19
, pp. 260-266
-
-
Fontoura, P.1
Steinman, L.2
Miller, A.3
-
6
-
-
0035885062
-
Strategies for optimizing adherence to highly active antiretroviral therapy: Lessons from research and clinical practice
-
Stone VE. Strategies for optimizing adherence to highly active antiretroviral therapy: lessons from research and clinical practice. Clin Infect Dis 2001; 33:865-872.
-
(2001)
Clin Infect Dis
, vol.33
, pp. 865-872
-
-
Stone, V.E.1
-
7
-
-
33645227849
-
Patient satisfaction with an injection device for multiple sclerosis treatment
-
Cramer JA, Cuffel BJ, Divan V, et al. Patient satisfaction with an injection device for multiple sclerosis treatment. Acta Neurol Scand 2006; 113:156-162.
-
(2006)
Acta Neurol Scand
, vol.113
, pp. 156-162
-
-
Cramer, J.A.1
Cuffel, B.J.2
Divan, V.3
-
8
-
-
0042932742
-
Interrupted therapy: Stopping and switching of the beta-interferons prescribed for MS
-
Tremlett HL, Oger J. Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS. Neurology 2003; 61:551-554.
-
(2003)
Neurology
, vol.61
, pp. 551-554
-
-
Tremlett, H.L.1
Oger, J.2
-
9
-
-
35348897458
-
Adherence to disease-modifying therapy for multiple sclerosis
-
February
-
Cohen BA. Adherence to disease-modifying therapy for multiple sclerosis. Int J MS Care 2006; (February Suppl):32-37.
-
(2006)
Int J MS Care
, Issue.SUPPL.
, pp. 32-37
-
-
Cohen, B.A.1
-
10
-
-
33746445987
-
Managing self-injection difficulties in patients with relapsing-remitting multiple sclerosis
-
Cox D, Stone J. Managing self-injection difficulties in patients with relapsing-remitting multiple sclerosis. J Neurosci Nurs 2006; 38:167-171.
-
(2006)
J Neurosci Nurs
, vol.38
, pp. 167-171
-
-
Cox, D.1
Stone, J.2
-
11
-
-
0035018884
-
Injectable medication for the treatment of multiple sclerosis: The influence of self-efficacy expectations and injection anxiety on adherence and ability to self-inject
-
Mohr DC, Boudewyn AC, Likosky W, et al. Injectable medication for the treatment of multiple sclerosis: the influence of self-efficacy expectations and injection anxiety on adherence and ability to self-inject. Ann Behav Med 2001; 23:125-132.
-
(2001)
Ann Behav Med
, vol.23
, pp. 125-132
-
-
Mohr, D.C.1
Boudewyn, A.C.2
Likosky, W.3
-
12
-
-
53249154843
-
Recognizing nonadherence in patients with multiple sclerosis and maintaining treatment adherence in the long term
-
Costello K, Kennedy P, Scanzillo J. Recognizing nonadherence in patients with multiple sclerosis and maintaining treatment adherence in the long term. Medscape J Med 2008; 10:225.
-
(2008)
Medscape J Med
, vol.10
, pp. 225
-
-
Costello, K.1
Kennedy, P.2
Scanzillo, J.3
-
13
-
-
67849109050
-
Medication gaps in disease-modifying therapy for multiple sclerosis are associated with an increased risk of relapse: Findings from a national managed care database
-
Al-Sabbagh A, Bennet R, Kozma C, et al. Medication gaps in disease-modifying therapy for multiple sclerosis are associated with an increased risk of relapse: findings from a national managed care database. J Neurol 2008; 255:S79.
-
(2008)
J Neurol
, vol.255
-
-
Al-Sabbagh, A.1
Bennet, R.2
Kozma, C.3
-
14
-
-
59049103985
-
Measuring adherence and persistence to disease-modifying agents among patients with relapsing remitting multiple sclerosis
-
Lafata JE, Cerghet M, Dobie E, et al. Measuring adherence and persistence to disease-modifying agents among patients with relapsing remitting multiple sclerosis. J Am Pharm Assoc (2003) 2008; 48:752-757.
-
(2003)
J Am Pharm Assoc
, vol.2008
, Issue.48
, pp. 752-757
-
-
Lafata, J.E.1
Cerghet, M.2
Dobie, E.3
-
15
-
-
67849109048
-
Comparison of adherence and persistence in patients initiating disease-modifying therapy for multiple sclerosis
-
7-11 June, Nice, France. p
-
Meletiche D, Shea TWF, Shim B, et al. Comparison of adherence and persistence in patients initiating disease-modifying therapy for multiple sclerosis. In: Proceedings of the 18th Meeting of the European Neurological Society (ENS); 7-11 June 2008; Nice, France. p. 323.
-
(2008)
Proceedings of the 18th Meeting of the European Neurological Society (ENS)
, pp. 323
-
-
Meletiche, D.1
Shea, T.W.F.2
Shim, B.3
-
16
-
-
0142017677
-
Adherence to long-term therapies: Evidence for action
-
World Health Organization
-
World Health Organization. Adherence to long-term therapies: evidence for action. World Health Organization Report 2003.
-
World Health Organization Report 2003
-
-
-
17
-
-
44449148293
-
The impact of medication regimen factors on adherence to chronic treatment: A review of literature
-
Ingersoll KS, Cohen J. The impact of medication regimen factors on adherence to chronic treatment: a review of literature. J Behav Med 2008; 31:213-224.
-
(2008)
J Behav Med
, vol.31
, pp. 213-224
-
-
Ingersoll, K.S.1
Cohen, J.2
-
18
-
-
12144288676
-
Adherence, quality of life, and general satisfaction with co-formulated zidovudine, lamivudine, and abacavir on anti-retroviral-experienced patients
-
Clotet B, Carmena J, Pulido F, et al. Adherence, quality of life, and general satisfaction with co-formulated zidovudine, lamivudine, and abacavir on anti-retroviral-experienced patients. HIV Clin Trials 2004; 5:33-39.
-
(2004)
HIV Clin Trials
, vol.5
, pp. 33-39
-
-
Clotet, B.1
Carmena, J.2
Pulido, F.3
-
19
-
-
33745788778
-
Benefits, challenges, and registerability of the polypill
-
Sleight P, Pouleur H, Zannad F. Benefits, challenges, and registerability of the polypill. Eur Heart J 2006; 27:1651-1656.
-
(2006)
Eur Heart J
, vol.27
, pp. 1651-1656
-
-
Sleight, P.1
Pouleur, H.2
Zannad, F.3
-
20
-
-
33645099736
-
Adherence, patient preference and dosing frequency: Understanding the relationship
-
Reginster JY, Rabenda V, Neuprez A. Adherence, patient preference and dosing frequency: understanding the relationship. Bone 2006; 38:S2-S6.
-
(2006)
Bone
, vol.38
-
-
Reginster, J.Y.1
Rabenda, V.2
Neuprez, A.3
-
21
-
-
4243119542
-
Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease
-
Atkinson MJ, Sinha A, Hass SL, et al. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes 2004; 2:12-24.
-
(2004)
Health Qual Life Outcomes
, vol.2
, pp. 12-24
-
-
Atkinson, M.J.1
Sinha, A.2
Hass, S.L.3
-
22
-
-
36148952124
-
Toward the development of rational therapies in multiple sclerosis: What is on the horizon?
-
Hemmer B, Hartung HP. Toward the development of rational therapies in multiple sclerosis: what is on the horizon? Ann Neurol 2007; 62:314-326.
-
(2007)
Ann Neurol
, vol.62
, pp. 314-326
-
-
Hemmer, B.1
Hartung, H.P.2
-
23
-
-
77955799815
-
Oral fingolimod (FTY720) for relapsing multiple sclerosis
-
Kappos L, Antel J, Comi G, et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 2006; 355:1124-1140.
-
(2006)
N Engl J Med
, vol.355
, pp. 1124-1140
-
-
Kappos, L.1
Antel, J.2
Comi, G.3
-
24
-
-
33645799680
-
A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses
-
O'Connor PW, Li D, Freedman MS, et al. A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology 2006; 66:894-900.
-
(2006)
Neurology
, vol.66
, pp. 894-900
-
-
O'Connor, P.W.1
Li, D.2
Freedman, M.S.3
-
25
-
-
15244353263
-
Treatment with laquinimod reduces development of active MRI lesions in relapsing MS
-
Polman C, Barkhof F, Sandberg-Wollheim M, et al. Treatment with laquinimod reduces development of active MRI lesions in relapsing MS. Neurology 2005; 64:987-991.
-
(2005)
Neurology
, vol.64
, pp. 987-991
-
-
Polman, C.1
Barkhof, F.2
Sandberg-Wollheim, M.3
-
26
-
-
22244480985
-
-
BG 12: BG 00012, BG 12/Oral Fumarate, FAG-201, second-generation fumarate derivative: Fumapharm/Biogen Idec. Drugs R D 2005; 6:229-230.
-
BG 12: BG 00012, BG 12/Oral Fumarate, FAG-201, second-generation fumarate derivative: Fumapharm/Biogen Idec. Drugs R D 2005; 6:229-230.
-
-
-
-
27
-
-
33947625032
-
Fumaric acid esters in the management of severe psoriasis
-
Brewer L, Rogers S. Fumaric acid esters in the management of severe psoriasis. Clin Exp Dermatol 2007; 32:246-249.
-
(2007)
Clin Exp Dermatol
, vol.32
, pp. 246-249
-
-
Brewer, L.1
Rogers, S.2
-
28
-
-
54149116366
-
Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: A multicentre, randomised, double-blind, placebo-controlled phase IIb study
-
Kappos L, Gold R, Miller DH, et al. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 2008; 372:1463-1472.
-
(2008)
Lancet
, vol.372
, pp. 1463-1472
-
-
Kappos, L.1
Gold, R.2
Miller, D.H.3
-
29
-
-
36348983293
-
The potential role for cladribine in the treatment of multiple sclerosis: Clinical experience and development of an oral tablet formulation
-
Leist TP, Vermersch P. The potential role for cladribine in the treatment of multiple sclerosis: clinical experience and development of an oral tablet formulation. Curr Med Res Opin 2007; 23:2667-2676.
-
(2007)
Curr Med Res Opin
, vol.23
, pp. 2667-2676
-
-
Leist, T.P.1
Vermersch, P.2
-
30
-
-
27944443692
-
Cladribine for multiple sclerosis: Review and current status
-
Sipe JC. Cladribine for multiple sclerosis: review and current status. Expert Rev Neurother 2005; 5:721-727.
-
(2005)
Expert Rev Neurother
, vol.5
, pp. 721-727
-
-
Sipe, J.C.1
-
31
-
-
0029983154
-
The treatment of chronic progressive multiple sclerosis with cladribine
-
Beutler E, Sipe JC, Romine JS, et al. The treatment of chronic progressive multiple sclerosis with cladribine. Proc Natl Acad Sci U S A 1996; 93:1716-1720.
-
(1996)
Proc Natl Acad Sci U S A
, vol.93
, pp. 1716-1720
-
-
Beutler, E.1
Sipe, J.C.2
Romine, J.S.3
-
32
-
-
0034646216
-
Cladribine and progressive MS: Clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group
-
Rice GP, Filippi M, Comi G. Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group. Neurology 2000; 54:1145-1155.
-
(2000)
Neurology
, vol.54
, pp. 1145-1155
-
-
Rice, G.P.1
Filippi, M.2
Comi, G.3
-
33
-
-
0032908474
-
A double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosis
-
Romine JS, Sipe JC, Koziol JA, et al. A double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosis. Proc Assoc Am Phys 1999; 111:35-44.
-
(1999)
Proc Assoc Am Phys
, vol.111
, pp. 35-44
-
-
Romine, J.S.1
Sipe, J.C.2
Koziol, J.A.3
-
34
-
-
67849100290
-
A combined analysis of data from four randomized, double-blind, placebo-controlled trials of parenteral cladribine and one open-label pilot study to assess the safety and tolerability profile of repeated periods of cladribine treatment in patients with progressive or relapsing multiple sclerosis
-
for the Cladribine Clinical Study Group, Presented at the 12-19 April, Chicago, Illinois
-
Cook SD, Gardner JD, Greenberg S, for the Cladribine Clinical Study Group. A combined analysis of data from four randomized, double-blind, placebo-controlled trials of parenteral cladribine and one open-label pilot study to assess the safety and tolerability profile of repeated periods of cladribine treatment in patients with progressive or relapsing multiple sclerosis. Presented at the 60th American Academy of Neurology Annual Meeting; 12-19 April 2008; Chicago, Illinois. P02.180.
-
(2008)
60th American Academy of Neurology Annual Meeting
-
-
Cook, S.D.1
Gardner, J.D.2
Greenberg, S.3
-
35
-
-
0027056958
-
On the bioavailability of oral and subcutaneous 2-chloro-20-deoxyadenosine in humans: Alternative routes of administration
-
Liliemark J, Albertioni F, Hassan M, et al. On the bioavailability of oral and subcutaneous 2-chloro-20-deoxyadenosine in humans: alternative routes of administration. J Clin Oncol 1992; 10:1514-1518.
-
(1992)
J Clin Oncol
, vol.10
, pp. 1514-1518
-
-
Liliemark, J.1
Albertioni, F.2
Hassan, M.3
-
36
-
-
67849109049
-
Oral Investigational Treatment Cladribine Tablets for Multiple Sclerosis Significantly Reduced Relapse Rate in Two-Year Phase III Pivotal Trial. Geneva
-
Accessed 23 January 2009
-
Merck Serono. Merck Serono's Oral Investigational Treatment Cladribine Tablets for Multiple Sclerosis Significantly Reduced Relapse Rate in Two-Year Phase III Pivotal Trial. Geneva. Merck Serono; 2009. http://www.merckserono.com/ corp.merckserono/en/images/20090123-en-tcm112-34916.pdf. [Accessed 23 January 2009]
-
(2009)
Merck Serono
-
-
-
37
-
-
47249153516
-
Modulating tone: The overture of S1P receptor immunotherapeutics
-
Rosen H, Gonzalez-Cabrera P, Marsolais D, et al. Modulating tone: the overture of S1P receptor immunotherapeutics. Immunol Rev 2008; 223: 221-235.
-
(2008)
Immunol Rev
, vol.223
, pp. 221-235
-
-
Rosen, H.1
Gonzalez-Cabrera, P.2
Marsolais, D.3
-
38
-
-
33748695513
-
Fingolimod and sphingosine-1- phosphatemodifiers of lymphocyte migration
-
Massberg S, von Andrian UH. Fingolimod and sphingosine-1- phosphatemodifiers of lymphocyte migration. N Engl J Med 2006; 355:1088-1091.
-
(2006)
N Engl J Med
, vol.355
, pp. 1088-1091
-
-
Massberg, S.1
von Andrian, U.H.2
-
39
-
-
53049085954
-
Central nervous system-directed effects of FTY720 (fingolimod)
-
Miron VE, Schubart A, Antel JP. Central nervous system-directed effects of FTY720 (fingolimod). J Neurol Sci 2008; 274:13-17.
-
(2008)
J Neurol Sci
, vol.274
, pp. 13-17
-
-
Miron, V.E.1
Schubart, A.2
Antel, J.P.3
-
40
-
-
33750736991
-
FTY720 (fingolimod) in renal transplantation
-
Budde K, Schutz M, Glander P, et al. FTY720 (fingolimod) in renal transplantation. Clin Transplant 2006; 20 (Suppl 17):17-24.
-
(2006)
Clin Transplant
, vol.20
, Issue.SUPPL. 17
, pp. 17-24
-
-
Budde, K.1
Schutz, M.2
Glander, P.3
-
41
-
-
67849085963
-
-
Reuters 5 June 2008, Accessed 15 December 2008
-
Cage S. Novartis says FTY720 trial continues despite death. Reuters 5 June 2008. http://uk.reuters.com/article/UK-SMALLCAPSRPT/idUKL0586762720080605? sp=true. [Accessed 15 December 2008]
-
Novartis says FTY720 trial continues despite death
-
-
Cage, S.1
-
42
-
-
54349101744
-
Identification and development of new therapeutics for multiple sclerosis
-
Linker RA, Kieseier BC, Gold R. Identification and development of new therapeutics for multiple sclerosis. Trends Pharmacol Sci 2008; 29:558-565.
-
(2008)
Trends Pharmacol Sci
, vol.29
, pp. 558-565
-
-
Linker, R.A.1
Kieseier, B.C.2
Gold, R.3
-
44
-
-
0036240732
-
Suppression of experimental autoimmune neuritis by ABR-215062 is associated with altered Th1/Th2 balance and inhibited migration of inflammatory cells into the peripheral nerve tissue
-
Zou LP, Abbas N, Volkmann I, et al. Suppression of experimental autoimmune neuritis by ABR-215062 is associated with altered Th1/Th2 balance and inhibited migration of inflammatory cells into the peripheral nerve tissue. Neuropharmacology 2002; 42:731-739.
-
(2002)
Neuropharmacology
, vol.42
, pp. 731-739
-
-
Zou, L.P.1
Abbas, N.2
Volkmann, I.3
-
45
-
-
45249107267
-
Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: A multicentre, randomised, double-blind, placebo-controlled phase IIb study
-
Comi G, Pulizzi A, Rovaris M, et al. Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 2008; 371:2085-2092.
-
(2008)
Lancet
, vol.371
, pp. 2085-2092
-
-
Comi, G.1
Pulizzi, A.2
Rovaris, M.3
-
46
-
-
25444448197
-
Disruption of the interaction of T cells with antigen-presenting cells by the active leflunomide metabolite teriflunomide: Involvement of impaired integrin activation and immunologic synapse formation
-
Zeyda M, Poglitsch M, Geyeregger R, et al. Disruption of the interaction of T cells with antigen-presenting cells by the active leflunomide metabolite teriflunomide: involvement of impaired integrin activation and immunologic synapse formation. Arthritis Rheum 2005; 52:2730-2739.
-
(2005)
Arthritis Rheum
, vol.52
, pp. 2730-2739
-
-
Zeyda, M.1
Poglitsch, M.2
Geyeregger, R.3
-
48
-
-
5044232705
-
Vasculitis associated with the use of leflunomide
-
Macdonald J, Zhong T, Lazarescu A, et al. Vasculitis associated with the use of leflunomide. J Rheumatol 2004; 31:2076-2078.
-
(2004)
J Rheumatol
, vol.31
, pp. 2076-2078
-
-
Macdonald, J.1
Zhong, T.2
Lazarescu, A.3
-
49
-
-
33846490253
-
Peripheral neuropathy associated with leflunomide: Is there a risk patient profile?
-
Martin K, Bentaberry F, Dumoulin C, et al. Peripheral neuropathy associated with leflunomide: is there a risk patient profile? Pharmacoepidemiol Drug Saf 2007; 16:74-78.
-
(2007)
Pharmacoepidemiol Drug Saf
, vol.16
, pp. 74-78
-
-
Martin, K.1
Bentaberry, F.2
Dumoulin, C.3
-
50
-
-
55349135951
-
Novel therapeutic strategies for multiple sclerosis: A multifaceted adversary
-
Lopez-Diego RS, Weiner HL. Novel therapeutic strategies for multiple sclerosis: a multifaceted adversary. Nat Rev Drug Discov 2008; 7:909-925.
-
(2008)
Nat Rev Drug Discov
, vol.7
, pp. 909-925
-
-
Lopez-Diego, R.S.1
Weiner, H.L.2
-
51
-
-
57149117126
-
New cases of progressive multifocal leukoencephalopathy after treatment with natalizumab
-
Hartung HP. New cases of progressive multifocal leukoencephalopathy after treatment with natalizumab. Lancet Neurol 2009; 8:28-31.
-
(2009)
Lancet Neurol
, vol.8
, pp. 28-31
-
-
Hartung, H.P.1
|